Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
February 21, 2014 16:01 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Present at the 2014 Leerink Global Healthcare Conference
February 06, 2014 06:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
February 04, 2014 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request
January 21, 2014 01:00 ET
|
Amarin Corporation plc
Conference Call Set for 8:00 a.m. ET today
Amarin Plans Appeal to FDA Office Level, No FDA sNDA Action Expected During Appeal
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 21, 2014 (GLOBE...
Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed
January 15, 2014 16:05 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed
December 20, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Leadership Changes
December 16, 2013 09:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Patent Allowances for U.S. Applications 13/685,281, and 13/685,291 Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations
December 02, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Reports Third Quarter 2013 Financial Results and Provides Update on Operations
November 07, 2013 16:02 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of...
Amarin to Report Third Quarter 2013 Results and Host Conference Call on November 7, 2013
October 31, 2013 16:05 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...